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SHORT REPORT
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ABSTRACT
In two pivotal efficacy studies (ZOE-50; ZOE-70), the adjuvanted recombinant zoster vaccine (RZV)
demonstrated >90% efficacy against herpes zoster (HZ).
Adults aged ≥50 or ≥70 years (ZOE-50 [NCT01165177]; ZOE-70 [NCT01165229]) were randomized to
receive 2 doses of RZV or placebo 2 months apart. Vaccine efficacy and safety were evaluated post-hoc
in the pooled (ZOE-50/70) population according to the number and type of selected medical conditions
present at enrollment.
At enrollment, 82.3% of RZV and 82.7% of placebo recipients reported ≥1 of the 15 selected medical
conditions. Efficacy against HZ ranged from 84.5% (95% Confidence Interval [CI]: 46.4–97.1) in partici-
pants with respiratory disorders to 97.0% (95%CI: 82.3–99.9) in those with coronary heart disease.
Moreover, efficacy remained >90% irrespective of the number of selected medical conditions reported
by a participant.
As indicated by the similarity of the point estimates, this post-hoc analysis suggests that RZV efficacy
remains high in all selected medical conditions, as well as with increasing number of medical conditions.
No safety concern was identified by the type or number of medical conditions present at enrollment.
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Introduction
Herpes zoster (HZ) results from reactivation of latent vari-
cella-zoster virus (VZV) in sensory ganglia long after primary
infection. Worldwide, the incidence of HZ ranges between
3–5 cases per 1,000 person-years in the general population
and increases markedly with age, with more than two-thirds
of HZ cases occurring in adults over 50 years of age (YOA).1,2
Medical conditions previously identified as increasing the risk
of HZ include systemic lupus erythematosus, rheumatoid arthri-
tis, inflammatory bowel disease, chronic obstructive pulmonary
disease, asthma, chronic kidney disease, renal failure, hyperten-
sion, diabetes mellitus (predominantly type I), depression, and
spinal disc herniation.3–5 The increase in HZ risk associated with
some of these conditions may result from the immunosuppressive
therapy prescribed to treat the disease and/or from underlying
cell-mediated immunosuppression associated with the disease.4
Vaccination decreases the risk of HZ.6–9 The adjuvanted
recombinant zoster vaccine (RZV, Shingrix), containing a
truncated form of VZV glycoprotein E and the AS01B adju-
vant system, demonstrated 97.2% and 91.3% vaccine efficacy
(VE) against HZ in adults ≥50 (ZOE-50) and ≥70 YOA (ZOE-
70), respectively, over an approximate 4-year follow-up per-
iod. Efficacy remained >90% among participants ≥80 YOA.7,8
RZV also demonstrated an acceptable safety profile.7,8,10 It is
currently licensed in multiple countries for the prevention of
HZ in adults ≥50 YOA.
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Although adults with a life expectancy of less than 4 years,
with immunosuppressive conditions (e.g., resulting from
malignancy or HIV infection) or requiring treatment with
immune-modifying drugs (e.g., medications used during can-
cer chemotherapy or organ transplantation) were excluded
from entry into the ZOE-50/70 trials,7,8 the eligibility criteria
allowed enrollment of adults with medical conditions that are
common in the general older adult population. The study
population was therefore considered broadly representative
of the general older adult population. The two studies were
conducted in parallel at the same sites and in an identical
manner, allowing the analysis of pooled data from both trials.
Adults ≥70 YOA were randomly assigned to the ZOE-50 or
ZOE-70 study before being randomized to a study group.
The objective of this post-hoc pooled analysis is to evaluate
RZV efficacy against the first or only episode of HZ and to
examine RZV safety in participants with selected medical
conditions at enrollment.
Methods
The ZOE-50/70 studies were phase III, randomized, observer-
blind, controlled trials conducted in parallel in 18 countries in
Europe, North America, Latin America, Asia and Australia in
adults ≥50 YOA (NCT01165177) and ≥70 YOA
(NCT01165229). Participants were randomized 1:1 to receive 2
doses of either RZV or saline placebo 2 months (M) apart.7,8
Protocol summaries are available for both studies at http://www.
gsk-clinicalstudyregister.com (studies 110390 and 113077).
Anonymized individual participant data and study documents
can be requested for further research from www.clinicalstudyda
tarequest.com.
Persons with a confirmed or suspected immunosuppressive
or immunodeficient conditions resulting from disease (e.g.,
malignancy, human immunodeficiency virus infection) or
immunosuppressive/cytotoxic therapy (e.g., medications used
during cancer therapy, organ transplantation or to treat auto-
immune disorders) were excluded. Persons who had received
immunosuppressants or immune-modifying drugs for >15
consecutive days within 6 months prior to the first vaccine
dose, were also excluded (prednisone <20 mg/day, or equiva-
lent, and inhaled/topical steroids were allowed). Full inclusion
and exclusion criteria have previously been published.7,8
Medical conditions of the approximately 30,000 partici-
pants were recorded at enrollment in the ZOE-50/70 trials,
and those most frequently reported in the ZOE-70 trial were
selected and applied for analysis utilizing data from both
trials, since the prevalence of most underlying medical condi-
tions increases with age. Efficacy and safety analyses were
performed post-hoc in the pooled ZOE-50/70 population (i)
according to medical conditions reported by at least 500
participants from either arm of the ZOE-70 study at enroll-
ment (considered to provide an adequate sample size for the
purpose of a descriptive analysis), and according to additional
medical conditions reported by less than 500 participants in
the ZOE-70 study at enrollment but associated with an
increased risk of HZ (asthma, depression, respiratory disor-
ders, and renal disorders),3–5 and (ii) according to the number
of selected medical conditions reported by study participants
at enrollment. For the purpose of the analysis, medical con-
ditions were defined as individual Medical Dictionary for
Regulatory Authorities preferred terms (PTs) or grouped
PTs representing conditions of similar pathophysiological
origin. Details on PT grouping are provided in the
Supplementary Table 1. Participants reporting more than
one of the PTs within the 15 selected medical conditions
were only counted once for the respective analyses.
For the analysis of VE, a suspected HZ case was defined as
new unilateral rash with pain that had no alternative diagnosis.
Participants were followed for at least 90 days after the onset of
HZ or until the rash resolved and the participant was pain-free
for 4 weeks. Suspected HZ cases were evaluated and confirmed
as described previously by polymerase-chain-reaction or an
adjudication committee.7,8 Efficacy was assessed similar to the
primary analysis on the pooled modified total vaccinated cohort
(mTVC).7,8 This included all participants from the pooled TVC
who had received both doses of vaccine/placebo and who had
not developed a confirmed HZ case prior to 30 days post-dose 2.
VE was defined as 1 minus the ratio of HZ incidence in the RZV
group to that in the placebo group.
For assessment of safety, serious adverse events (SAEs)
were recorded for all participants for up to 12 months post-
dose 2; any events resulting in death, and potentially immune-
mediated diseases (pIMDs) were evaluated in all participants
over the entire study period. Safety was evaluated in the
pooled TVC from the ZOE-50/70 studies, which included all
participants administered with at least one dose of RZV.
Results
Of the 30,977 participants enrolled in the ZOE-50/70 studies,
13,881 RZV and 14,035 placebo recipients were included in
the mTVC. Of these, 82.3% of RZV recipients and 82.7% of
placebo recipients had at least 1 of the 15 selected medical
conditions at enrollment. A majority (RZV: 59.6%, Placebo:
59.8%) had 2 or more (Figure 1). In the pooled mTVC,
demographic characteristics, including proportions of partici-
pants reporting each of the selected medical conditions, were
balanced between study groups (Table 1).
Medical conditions in order of decreasing frequency
included hypertension, osteoarthritis and vertebral disorders,
and dyslipidemia. The most frequently reported conditions
known to increase HZ risk included in this analysis were
depression and asthma (Table 1).
Efficacy against HZ ranged from 84.5% (95% Confidence
Interval [CI]: 46.4–97.1) in participants with respiratory dis-
orders to 97.0% (95% CI: 82.3–99.9) in those with coronary
heart disease at enrollment. Efficacy was 88.8% (95% CI: 63.6–
97.8) in participants with asthma, and 91.2% (95% CI: 81.1–
96.6) in those with diabetes. The only medical condition that
RZV efficacy did not achieve statistical significance was renal
disorders (VE: 86.6% [95% CI: −4.5–99.7]). The low number
of participants with this condition limited the statistical power
to assess VE. Overall, RZV efficacy was >90% irrespective of
the number of the selected medical conditions reported at
enrollment by a participant (Table 2).
In RZV or placebo recipients reporting at least 1 of the 15
selected medical conditions at enrollment, the proportion of
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participants experiencing SAEs or deaths was highest among
those with chronic conditions such as renal disorders, respira-
tory disorders, or coronary heart disease. The numbers of
SAEs, deaths, or pIMDs were similar in the vaccine and
placebo groups for each of the medical conditions (Table 3).
The frequency of SAEs and deaths increased with the number
of medical conditions present at enrollment; however, the
frequency of pIMDs did not. Frequencies of SAEs, deaths,
and pIMDs were balanced between RZV and placebo recipi-
ents reporting any number of these conditions (Table 3).
Discussion
Older adults enrolled in the ZOE-50/70 studies reported under-
lying medical conditions at a frequency expected in these age
groups.11 The observed efficacy across the 15 medical condi-
tions, including the ones associated with an increased HZ risk,
was consistent with the efficacy in the overall pooled ZOE-50/70
population ≥70 YOA.8 This is in line with the fact that >80% of
the overall ZOE-50 and ZOE-70 study population reported at
least 1 of the specified conditions. Other studies have shown that
RZV also confers strong protection against HZ in immunocom-
promised populations who are at highest HZ risk, such as
hematopoietic stem cell transplant recipients and patients with
hematological malignancies.12,13
The high proportion of participants reporting at least 1 of the
selected medical conditions can be explained by the relatively
permissive inclusion and exclusion criteria for the ZOE-50/70
studies and the age of study participants. Previous studies have
shown that frailty correlates with the number, rather than the
nature of accumulated biopsychosocial deficits, which are mostly
medical conditions.14,15 Our analysis was consistent with this
finding in that the frequency of SAEs and deaths increased with
the number of conditions reported at enrollment. Although the
point estimates for efficacy were <90% for 5 of the 15 selected
medical conditions, the observed trend suggest that a high VEwas
maintained in participants having up to 6 or more of those con-
ditions. This contrasts with the observed decline in influenza
vaccination effectiveness as the level of frailty increases in elderly
people.16 This further underscores the ability of RZV to induce
30,977 participants enrolled in the studies 
30,960 randomized to a study group
15,476 assigned to RZV 15,484 assigned to Placebo
14,645 vaccinated (TVC) 14,660 vaccinated (TVC)
13,881 included in the mTVC for 
efficacy assessment
14,035 included in the mTVC for 
efficacy assessment
Reasons for exclusion:
• 7     Did not receive vaccine according to protocol
• 21   Received wrong intervention
• 728 Did not receive dose 2
• 8     Had diagnosis of HZ <30 days after dose 2
17 not assigned to a study group
Reasons for exclusion:
• 6     Did not receive placebo according to protocol
• 13   Received wrong intervention
• 581 Did not receive dose 2
• 25   Had diagnosis of HZ <30 days after dose 2
Reasons for exclusion:
• 819 Had Good Clinical Practice violation
• 12   Did not receive intervention
Reasons for exclusion:
• 815 Had Good Clinical Practice violation
• 9     Did not receive intervention
11,427 (82.3%) reported at least 1 of the 15 selected current 
medical conditions at enrollment
11,608 (82.7%) reported at least 1 of the 15 selected current 
medical conditions at enrollment
8,268 (59.6%) reported at least 2 of the 15 selected current 
medical conditions at enrollment
8,397 (59.8%) reported at least 2 of the 15 selected current 
medical conditions at enrollment
Figure 1. Participant flow (pooled ZOE-50/70 studies) RZV = participants receiving the adjuvanted recombinant zoster vaccine; Placebo = participants receiving
placebo; ZOE-50/70 = RZV efficacy studies in adults ≥50 YOA (NCT01165177) and ≥70 YOA (NCT01165229), respectively; (m)TVC = (modified) total vaccinated cohort;
HZ, herpes zoster.
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robust protection against HZ in older adults withmultiplemedical
conditions.
Overall, frequencies of SAEs, deaths, and pIMDs were
balanced between RZV and placebo recipients within each
of the analyzed sub-groups. No vaccine-related safety con-
cerns were identified in participants with any type or number
of the selected medical conditions.
This post-hoc analysis has some limitations that should be
taken into account when interpreting its results. The ZOE-50/
70 studies were not statistically powered to evaluate RZV
efficacy and safety by the number and type of participants’
medical conditions. In addition, the number of participants in
some sub-groups was limited. This includes medical condi-
tions reported by less than 500 participants in the ZOE-70
study at enrollment but associated with an increased risk of
HZ (asthma, depression, respiratory disorders, and renal dis-
orders) and participants with ≥6 of the selected conditions.
The present analysis was not adjusted for multiplicity, and
being exploratory, its significance level was not controlled.
The efficacy and safety analyses by medical condition category
did not detect any additional underlying medical condition at
enrollment that might have an additive or synergistic effect on
the risk of HZ. As the study groups were comparable as a
result of randomization, this should have a limited effect on
the analyses by type or number of conditions. In addition,
study participants were not fully representative of the overall
older adult population. Individuals with a life expectancy of
less than 4 years at the time of study entry were to be
excluded. Persons with diseases requiring treatment with
immune-modifying drugs, as well as persons with diseases
that are immunosuppressive by nature, were also excluded,
limiting the conditions for which we could provide a VE
estimate. Therefore, owing to the inclusion/exclusion criteria,
persons with some of the conditions associated with the high-
est HZ risk were not enrolled in the study. Some of these
conditions were studied as part of the parallel clinical pro-
gram with RZV in immune compromised adults (e.g. hema-
topoietic stem cell transplant recipients and patients with
hematological malignancies). No standard definitions were
used in the diagnosis; therefore, each selected medical condi-
tion could vary with respect to severity, stage, treatment,
progression, or type (e.g., diabetes mellitus type). The data-
base did not capture this level of detail. Medical conditions
with onset after enrollment were not considered for this
analysis. Older adults with severe frailty (e.g., bedridden
elderly persons) were also unlikely to participate. Despite
their broad geographic diversity, study participants were
mostly Caucasian. Nonetheless, the most common diseases
in the targeted age group were well represented.
In summary, this study showed that >80% of participants
had at least 1 of the 15 selected medical conditions present at
enrollment. As indicated by the similarity of the point esti-
mates, this post-hoc analysis suggests that RZV efficacy
remains high in all selected medical conditions, as well as
with increasing number of medical conditions. Point esti-
mates for efficacy ranged between 84.5–97.0% according to
the type of the selected medical conditions (with overlapping
95% confidence intervals) and were >90% even among parti-
cipants reporting at least 6 of these at enrollment. No safety
concern was identified in adults ≥50 YOA presenting these
medical conditions.
A plain language summary contextualizing the results and
potential clinical research relevance and impact is displayed in
the Focus on Patient Section (Supplementary Figure 1).
Table 1. Demographic characteristics (pooled ZOE-50/70 modified Total Vaccinated Cohort).
RZV (N = 13,881) Placebo (N = 14,035)
Age (years)
Mean age at first dose ± SD 68.5 ± 9.8 68.5 ± 9.8
Gender, n (%)
Female 8,044 (57.9) 8,178 (58.3)
Male 5,837 (42.1) 5,857 (41.7)
Geographic ancestry, n (%)
White – Caucasian/European 10,321 (74.4) 10,403 (74.1)
Asian – East Asian 1,908 (13.7) 1,926 (13.7)
Asian – Japanese Heritage 575 (4.1) 591 (4.2)
African/African American 200 (1.4) 183 (1.3)
Other 877 (6.3) 932 (6.6)
Selected medical conditions present at enrollment, n (%)
Hypertension 7,206 (51.9) 7,226 (51.5)
Osteoarthritis and/or vertebral disorders 4,951 (35.7) 5,032 (35.9)
Dyslipidemia 4,628 (33.3) 4,707 (33.5)
Diabetes 2,350 (16.9) 2,372 (16.9)
Osteoporosis/Osteopenia 1,481 (10.7) 1,528 (10.9)
Gastroesophageal reflux disease 1,334 (9.6) 1,313 (9.4)
Sleep disorder 1,304 (9.4) 1,309 (9.3)
Prostatic diseases 1,244 (9.0) 1,285 (9.2)
Hypothyroidism 1,167 (8.4) 1,147 (8.2)
Depression 1,017 (7.3) 987 (7.0)
Coronary heart disease 1,003 (7.2) 1,055 (7.5)
Cataract 782 (5.6) 800 (5.7)
Asthma 646 (4.7) 689 (4.9)
Respiratory disorders# 614 (4.4) 560 (4.0)
Renal disorders 308 (2.2) 300 (2.1)
RZV = participants receiving the adjuvanted recombinant zoster vaccine; Placebo = participants receiving placebo; ZOE-50/70 = RZV efficacy studies in adults ≥50
YOA (NCT01165177) and ≥70 YOA (NCT01165229); N = number of participants in the pooled modified total vaccinated cohorts; n (%) = number (percentage) of
participants in each category; SD = standard deviation.
#Other than asthma.
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